Contemporary Targeted Therapies in RheumatologyJosef S. Smolen, Peter E. Lipsky CRC Press, 18 oct 2007 - 636 páginas Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other cytokines as well as specific cells and pathways involved in the path |
Índice
| 1 | |
| 7 | |
Chapter 3 Regulatory T cells | 23 |
Chapter 4 Bcell antigen receptor signaling and autoimmunity | 31 |
Chapter 5 Macrophages in rheumatoid arthritis | 45 |
Chapter 6 Dendritic cells | 63 |
Chapter 7 Osteoclasts | 79 |
Chapter 8 Cell contact dependence of inflammatory events | 85 |
Chapter 27 Complement and pregnancy loss | 339 |
Chapter 28 Matrix metalloproteinases | 353 |
Chapter 29 MMPs and ADAMs as targets for therapies in arthritis | 367 |
Chapter 30 Update on proinflammatory cytokine blockade in rheumatoid arthritis | 385 |
Chapter 31 Targeting interleukin1 in rheumatic diseases | 391 |
Chapter 32 Update on targeted therapy in psoriatic arthritis | 401 |
Chapter 33 Spondyloarthritides | 413 |
Chapter 34 Early Arthritis | 419 |
possible targets for novel treatments for rheumatoid arthritis | 105 |
a new therapeutic target in inflammatory arthritis | 121 |
Chapter 11 TNFα | 133 |
Chapter 12 Update on interleukin6 | 149 |
Chapter 13 Interleukin13 | 159 |
Chapter 14 Biology of interleukin15 | 175 |
a new target in arthritis | 185 |
Chapter 16 The role of interleukin18 in inflammation | 195 |
Chapter 17 Interleukin21 | 211 |
Chapter 18 The biology of human interleukin32 | 225 |
Chapter 19 The interferons | 231 |
Chapter 20 Osteoprotegerin | 251 |
inflammatory angiogenic and homeostatic chemokines and their receptors | 265 |
Chapter 22 New developments in NFkB | 285 |
Chapter 23 Roles of the JAKSTAT signaling pathways in rheumatoid arthritis | 297 |
Chapter 24 Suppressor of cytokine signaling SOCSproteins as therapeutic targets in rheumatoid arthritis | 305 |
Chapter 25 Wnt signaling for targeted therapies in rheumatology | 317 |
update on cyclooxygenases and prostaglandin synthases | 329 |
Chapter 35 Juvenile arthritis | 425 |
Chapter 36 Update systemic lupus erythematosus | 435 |
Chapter 37 Vasculitis | 449 |
Chapter 38 Myositis | 467 |
Chapter 39 TNF blockade in orphan rheumatic diseases | 485 |
Chapter 40 Overview of the safety of TNF inhibitors | 497 |
Chapter 41 AntiCD20 to further targeted therapies in rheumatology | 509 |
a therapeutic promise waiting to be fulfilled | 527 |
Chapter 43 AntiCD3 antibody a history of successful immune interventions | 543 |
Chapter 44 Alefacept | 553 |
Chapter 45 Clinical targeting of interleukin15 | 561 |
Chapter 46 Clinical prospects of MAPK inhibitors | 569 |
Chapter 47 Clinical prospects of NFκB inhibitors to further targeted therapies in rheumatology | 581 |
Chapter 48 Outcomes assessment in rheumatic disease | 601 |
| 617 | |
Back Cover | 635 |
Otras ediciones - Ver todo
Contemporary Targeted Therapies in Rheumatology Josef S. Smolen,Peter E. Lipsky No hay ninguna vista previa disponible - 2007 |
Términos y frases comunes
activation addition agents antibody antigen Arthritis Rheum associated autoimmune binding Biol biologic blocking blood BLyS bone cartilage cells chemokine chronic Clin clinical combination compared complex controlled cytokines demonstrated dendritic cells destruction differentiation disease domain dose drugs early effects efficacy et al evidence expression factor fibroblasts Figure function gene growth human immune Immunol important improvement increased induced infection inflammation inflammatory infliximab inhibition inhibitors interactions involved joint kinase leads levels ligand lupus lymphocytes macrophages mechanisms mediated methotrexate mice MMPs models molecules monocytes Nature necrosis factor observed pathway patients phase potential prevent production proinflammatory protein recent receptor reduced regulation regulatory reported response rheumatoid arthritis Rheumatol role selective serum severe showed shown signaling specific stimulated suggest suppression synovial synovial fluid systemic T-cell target therapeutic therapy tion tissue treated treatment trial tumor necrosis vitro vivo weeks